Langerhans cell histiocytosis: a multisystem disorder
نویسندگان
چکیده
منابع مشابه
Langerhans cell histiocytosis: a multisystem disorder.
Langerhans cell histiocytosis can involve single or multiple organ/tissue systems and may go undiagnosed for years until it enters the clinician's differential diagnosis framework. We report on a young patient who initially presented with diabetes insipidus and subsequently with pyrexia of unknown origin. She progressed from single system Langerhans cell histiocytosis to multisystem involvement...
متن کاملMultisystem Langerhans Cell Histiocytosis in Adult
Langerhans cell histiocytosis (LCH), is a rare disorder, clinically presents with heterogeneous manifestations, and has an unpredictable outcome. Commonly seen in infancy or early childhood, the disorder is characterized by proliferation of abnormal and clonal Langerhans cell in skin, bone, lymph nodes, lungs, liver, spleen, and bone marrow. Occurrence of LCH in adults is rare. Here, we report ...
متن کاملLangerhans cell histiocytosis
Introduction: Langerhans cell histiocytosis (LCH), which was previously known as histiocytosis X, refers to a group of lesions that stimulate uncontrolled proliferation of cells. The purpose of this case was to report and describe a LCH case with mandibular bone involvement in a 2.5-year-old boy. Case reports: A 2.5 years old boy with LCH of mandibular jaw who has been treated by surgical inter...
متن کاملA rare case of oral multisystem Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is a rare disorder characterized by high proliferation of Langerhans dendritic cells. LCH is a solitary or multifocal disease that primarily involves bone tissue and often affects children and young men. A 29 years-old Caucasian man was referred to the Oral Surgery Unit of George Eastman Hospital - Umberto I teaching hospital, with third degree mobility of te...
متن کاملTherapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Langerhans cell histiocytosis (LCH)-III tested risk-adjusted, intensified, longer treatment of multisystem LCH (MS-LCH), for which optimal therapy has been elusive. Stratified by risk organ involvement (high [RO+] or low [RO-] risk groups), > 400 patients were randomized. RO+ patients received 1 to 2 six-week courses of vinblastine+prednisone (Arm A) or vinblastine + prednisone + methotrexate (...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Journal of the Royal College of Physicians of Edinburgh
سال: 2012
ISSN: 1478-2715,2042-8189
DOI: 10.4997/jrcpe.2012.406